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Introduction
The 'histone code' is a well-established hypothesis describing the idea that specific patterns of post-translational modifications to histones act like a molecular 'code' recognized and used by nonhistone proteins to regulate specific chromatin functions [1] [2] [3] . One modification that has received significant attention is that of histone acetylation. The enzymes that regulate this modification are Epigenetics Review Series [4, 5] , and histone deacetylases or HDACs (Table 1) [6] . Although originally the activities of these enzymes were thought to only occur on histones, it is now well established that these enzymes can also alter non-histone proteins [7, 8] . Due to their conserved catalytic domain HDACs have been actively targeted as a therapeutic target [9, 10] .
In the following sections we will describe the evidence emerging from in vitro (cell culture) 
and in vivo (animal models) studies which indicate the usefulness of agents targeting HDACs in the treatment of disease using models of cancer, diabetes and neurodegenerative disease, and finish by describing the current emerging data from human clinical trials supporting the use of these drugs in the treatment of these diseases.

HATs/HDACs and the pro-inflammatory environment
Inflammation is a critical component that is increasingly being associated with cancer [11, 12] , diabetes [13] and neurodegenerative disease [14] . Fig. 1 [15] [16] [17] . These interactions were found to involve the RelA/p65 subunit. Another lysine acetyltransferase KAT13A was found to also potentiate NF-B transactivation through interactions with the other subunit p50 [18] . Following the identification of interactions between NF-B and lysine acetyltransferases it was subsequently shown that the RelA/p65 subunit could associate with HDAC1 and HDAC2 to repress expression of NF-B regulated genes as well as to control the induced level of expression of these genes [19] . RelA/p65 [22, 23] .
Histone modifying enzymes such as histone deacetylases have been identified as critical regulators of pro-inflammatory cascades. One of the best-established mechanisms identified concerns the roles of these enzymes in the regulation of nuclear factor B (NF-B) activation, as summarized in
. The NF-BRel family consists of five subunits, but NF-B typically consists of a heterodimeric protein comprising a p50 and a p65 (RelA) subunit. Early studies identified the lysine acetyltransferases KAT3B and KAT3A as key coactivators in regulating NF-B driven gene expression
It has since been shown that the histone deacetylase Sirtuin 1 (SIRT1) regulates NF-B transactivation by physically interacting with the RelA/p65 subunit of NF-B and inhibiting transcription by deacetylating a critical lysine at position 310 [20]. Both in vitro and in vivo exposure to cigarette smoke causes dose-and timedependent decrease in SIRT1 protein and deacetylase activity resulting in increased NF-B dependent pro-inflammatory mediator release [21]. One of the critical regulators of NF-B activation is IB kinase-␣ (IKK-␣), where NF-B transcription requires IKK-␣ to phosphorylate silencing mediator for retinoic acid and thyroid hormone receptor, which stimulates the exchange of corepressor for coactivator complexes. In the initial stage of NF-B activation, following this phosphorylation event HDAC3 is displaced, and this allows KAT3B to acetylate
Daxx is another protein that has been shown to regulate NF-B activation by binding to a region that includes the major sites of acetylation mediated by KAT3B/KAT3A [24] . However, it must be noted that Daxx has also been shown to directly associate with 
Class
HDAC members associated with References
I HDAC1, HDAC2, HDAC3, HDAC8 [6] IIA HDAC4, HDAC5, HDAC7, HDAC9 [359] IIB HDAC6, HDAC10 [360] III SIRT 1-7 [6] IV HDAC11 [360] 
HATs/HDACs and endoplasmic reticulum (ER) stress
The ability of a cell to sense, respond to and circumvent stress is essential for maintaining homeostasis. There are many ways in which stress, either endogenous or exogenous, can be manifested in a cell; these include pathogenic infection, chemical insult, genetic mutation, nutrient deprivation and even normal differentiation. The process of mutant protein folding is particularly sensitive to such insults. As such for the cellular compartments in which mutant proteins are processed and folded, there are adaptive programs that enable both their detection and correction for more efficient processing [33] . 
The ER is a large cellular organelle comprising a network of interconnected, closed membrane-bound vesicles. It is the site of synthesis, folding and modification of secretory and cell-surface proteins and serves many essential functions, including the production of the components of cellular membranes, proteins, lipids and sterols [34]. Only correctly folded proteins are transported out of the ER while incompletely folded proteins are retained in the organelle to complete the folding process or to be targeted for destruction [35]. Due to the important roles of this organelle, its proper functioning is essential to cellular homeostasis. However, various conditions can interfere with the ER function leading to ER stress. Stress is the response of any system to perturbations of its normal state. Thus, ER stress can arise from a disturbance in protein folding which results in an accumulation of unfolded or misfolded proteins within the organelle [36]. During such disturbances, in order to carry out the correct folding of proteins, the ER has evolved as a specialized protein-folding machine with cellular mechanisms that promote proper folding of aberrant protein, thus preventing its aggregation. Therefore, when ER homeostasis is altered by misfolded proteins, the ER responds by inducing the expression of specific genes in an attempt to restore normal ER function to and maintain stability [37]. The principle mechanisms of conformational disorders contained within the four pillars of ER stress: (i) protein degradation, (ii) endoplasmic overload response (EOR), (iii) unfolded protein response (UPR
Increased radiation sensitivity has been observed for a novel HDi (LBH589) targeting the classes I and II HDACs. Clonogenic survival showed that there was a greater than additive effect when LBH589 was administered prior to irradiation compared with irradiation alone. Subsequent in vivo tumour volume studies showed a growth delay of 20 days with combined treatment compared with 4 (radiation) and 2 days (LBH589) [143]. A similar increase in radiation sensitivity has also been observed in lung cancer cells treated with the HDi (NVP-LAQ824) [144]. Activating mutations of the epidermal growth factor receptor (EGFR) play critical roles in NSCLC survival, and have led to the development of targeted therapies [145]. A study examining a combination of the EGFR tyrosine kinase inhibitor erlotinib in combination with the HDi LBH589 found synergistic effects on lung cancer cells dependent on EGFR for growth and/or survival, and triggered apoptosis only in lung cancer cells which harboured EGFR mutations indicating that HDi treatments in NSCLC may prove to be of benefit to those patients which harbour EGFR mutations [146]. Another combinatorial treatment which shows efficacy in NSCLC cell lines involves TSA and etoposide, where co-treatment with these drugs induced apoptotic cell death in drug-resistant NSCLC cells, extending the notion that HDAC inhibitors in combination with conventional chemotherapeutic drugs could be a valuable therapeutic option in the treatment of NSCLC cancer [147].
Finally, a combination of an anti-inflammatory drug Sulindac, and SAHA has been shown to significantly enhance growth suppression and apoptosis in a NSCLC cell line, primarily through an enhancement of mitochondrial membrane potential collapse, release of cytochrome c and caspase activation [148] .
Hepatocellular carcinoma (HCC)
Another cancer for which strong evidence exists linking the activities of lysine acetyltransferases and histone deacetylases to disease is HCC. In agreement with NSCLC, altered patterns of both DNA CpG methylation [149] , and histone modifications [150] have also been observed in HCC.
We initially described the overexpression of histone deacetylases in the paediatric liver tumour hepatoblastoma [151] . Recent studies have shown that in patients with HCC high expression of HDAC1 was correlated with a higher incidence of cancer cell invasion into the portal vein, a poorer histological differentiation, a more advanced tumour node metastasis stage and had poorer prognosis [152] . In a gene microarray analysis of HCCs poor prognosis was observed for a subset of patients, which had elevated levels of various histone, modifying enzymes including HDAC2 [153] . Further evidence for the importance of histone deacetylases in the liver comes from transgenic mice overexpressing HDAC1. These mice exhibit a high incidence of hepatic steatosis [154] . As non-alcoholic steatohepatitis frequently develop HCC [155] [156, 157] , while a subunit of the TFTC/STAGA histone acetyltransferase complex has also been shown to be deregulated in HCC [158] . Finally, metastatic tumour antigen 1 MTA1 is another gene frequently overexpressed in HCC [159] [160] [161] [162, 163] . TSA and sodium butyrate were subsequently shown to decrease telomerase activity in hepatoma cell lines in addition to decreasing cellular proliferation [164] . TSA was shown to increase the activation of caspase-3 and promote apoptosis in hepatoma cells [165, 166] . [167] [168] [169] [170] . Proteomic analysis of hepatoma cells treated with SAHA identified 55 differentially expressed proteins of which 34 were subsequently identified using mass spectrometry analysis [171] . We also demonstrated the efficacy of 4-phenylbutyrate in inducing apoptosis and tumour remission in hepatoma tumour xenografts [172] . Similar results were obtained for the HDi HA-But. This is a butyric acid coupled to hyaluronic acid via an esterification, and which has strong affinity for the CD44 membrane receptor. Most importantly, this compound had strong uptake into liver and was able to prevent hepatic metastases in a xenograft model in vivo [173] .
. This protein has been shown to associate with various histone deacetylase complexes and further links aberrant chromatin remodelling activities to HCC [88, 91, 92].
In vitro evidence for the use of HDi in liver cancer
We initially indicated that TSA might have use as a therapeutic modality in the treatment of HCC. Treatment of HCC cell lines with TSA was found to dramatically increase the expression of cyclin dependent kinase inhibitors, insulin-like growth factor binding protein-3 and transforming growth factor ␤ (TGF-␤), the overexpression of which are commonly associated with cell cycle arrest and/or apoptosis
Using gene microarray profiling, we and others have examined the global gene expression changes for several HDi in hepatoma cells and identified many genes functionally altered following treatments of HDi
Recently a new phenylbutyrate-derived HDi has been developed which shows strong antitumour activity in hepatoma models both in vitro (cell line) and in vivo (xenograft) even in xenografts with high tumour burden (Ͼ500 mm
3 ) [174] .
Treating hepatoma cells with sodium butyrate researchers demonstrated that MMP-1 was being down-regulated, which correlated with a decreased ability to invade a matrigel assay [175] . Other HDi have also been shown to induce apoptosis in hepatoma cells including VPA and ITF2357 [176] 
Combinatorial treatments involving HDi in hepatoma Similarly to NSCLC, epigenetic targeting using a combination of HDi and demethylating agents have shown promise in an in vivo xenograft hepatoma model [179]. For instance, a triple combination of SAHA, irinotecan and 5-flurouracil (5-FU) led to a significant induction of apoptosis and cell death in hepatoma cells (92% after 72 hrs). Significantly, the double combination of irinotecan and 5-FU only led to a moderate increase in apoptosis and proliferation inhibition [180].
VPA has also been used to sensitize hepatoma cells to apoptosis in combination with the chemotherapy drug epirubicin [ [193] . Most recently, both TSA and SAHA were shown to prevent cytokine-induced toxicity in pancreatic ␤ cells [194] . 
Additional in vitro evidence
Stem cells, HDACs and histone deacetylase inhibitors
A currently hotly pursued therapeutic avenue for diabetes centres on embryonic stem (ES) cell technology [196] . Evidence is emerging indicating that histone deacetylases may be an important consideration in the development of this technology. Indeed histone deacetylase activity has been shown to be required for ES cell differentiation [197] . The importance of HDAC inhibitors in differentiating ES cells in general has been reviewed recently elsewhere and the reader is directed to the following reviews [198, 199] .
Nicotinamide, a SIRT-specific inhibitor, was also used to differentiate ES cells into structures resembling pancreatic islets and which secreted insulin [200] [201] . Using BMSCs derived from diabetic patients, similar results were obtained using Nicotinamide as one of the final steps in the differentiation process [202] . [203] [206] . Most recently it has now been demonstrated that HDACs play important roles in both neuron differentiation [207] , expression of neuron-specific genes [208] , and indeed regulate diverse cues such as maternal grooming [209] , and addiction [210] .
Two recent articles have utilized the HDi sodium butyrate to (i) stimulate early pancreatic development in ES cells
One [219] . 
HDACs play important roles in stem cell neuronal differentiation
Histone deacetylase inhibitors
SAHA has been the first directed HDi which has been FDA approved for the treatment of advanced primary cutaneous T-cell lymphoma [240] . In the following sections we will discuss the pharmacological and clinical data emerging from clinical trials using HDi (Table 2) . Furthermore we will also discuss one of the issues emerging within the literature on whether the therapeutic efficiency of HDi is via transcriptional mechanisms, or through their ability to enhance chaperone activity.
• Initial pharmacological and clinical data Several studies have attempted to examine the pharmacological clearance of HDi. Initial studies on TSA showed that it undergoes intensive phase I biotransformation in rat hepatocytes, which has important consequences for its potential development as a drug, as this will lead to poor in vivo bioavailability of this drug [241] . These results were subsequently confirmed in a mouse model using intraperitoneal administration of TSA [242] .
In [253] . Two phase I studies found that the DLTs included reversible neurocortical toxicity characterized by somnolence and confusion [254] [255] [256] . In a phase I study of sodium phenylbutyrate on patients with Huntington's disease, toxicities observed at the higher doses included vomiting, lightheadedness, confusion and gait instability, but with no significant laboratory or electrocardiographic abnormalities [257] . [264] . A phase II trial of VPA has also been completed in patients with castration-resistant prostate cancer. However, VPA was not found to be well tolerated by this cohort, and could not be administered reliably in order to achieve consistent levels or duration, and it was concluded that oral VPA is not recommended for prostate cancer [265] .
Valproic acid
VPA has also entered clinical trials as a stand-alone agent in patients with advanced refractory cancer. Dose escalation was carried out in three-patient cohorts on twenty-six pre-treated patients. The MTD of infused drug was found to be 60 mg/kg/day, and the DLT was found to be grade 3 or 4 neurological side effects occurring in 8 out of 26 patients
In a phase I trial of continuous oral VPA for maintenance treatment in heavily pre-treated paediatric glioma patients, moderate tumour efficacy was observed [266] . [267] 
VPA also shows potential in the treatment of neurodegenerative conditions. In a phase I trial of VPA on patients with human T-lymphotropic virus type 1 (HTLV-1), which is responsible for HTLV-associated myelopathy/tropical spastic paraparesis, clinical efficacy was observed. 16 patients were recruited and VPA was administrated orally at a maximal dose of 20 mg/kg/day. There was a significant drop in patient viral load from month 0 to month 3, and for the first time provides evidence that VPA leads to depletion of HTLV-1-infected cells in vivo
AN-9
The drug Pivanex [268, 269] . During the phase II trial, similar tolerance was observed, with the worst effects including fatigue and hypokalemia [269] . [270] [271] [272] [273] . [280] . However, in a phase II study of romidepsin in neuroendocrine tumours, the study was terminated prematurely due to an unexpected high number of serious cardiac adverse events [281] . [286] . [287] .
CI-994
For the inhibitor CI-994 several phase I studies have been completed. The principal DLT observed for all trials was thrombocytopenia, but other side effects observed included nausea, vomiting diarrhoea and mucositis
Romidepsin
The HDi romidepsin has completed several phase I clinical trials on cancer and has also entered/completed phase II trials. In the phase I trials the major DLTs for this drug was again thromocytopenia. However, for this drug a significant increase in reversible cardiac dysrhythmias and non-specific ECG abnormalities were observed [274-276]. In a phase I dose-escalation trial of romidepsin in paediatric solid tumours romidepsin was administered as a 4-hr infusion weekly for three consecutive weeks every
MS-275
MS-275 has just completed two phase I trials in solid tumours
LBH589 (panobinostat)
LBH5985 is currently undergoing an ongoing phase I, openlabel, dose-escalation study in patients with solid tumours and non-Hodgkin's lymphoma. From this study, 10 patients with CTCLs were treated with oral panobinostat on a 28-day cycle. From this initial cohort of 10 patients complete responses were observed in 2 patients and partial responses in a further 4 individuals. The major DLT observed was a grade 3 diarrhoea at a dose of 30 mg
MGC D0103
This orally administered HDi has recently completed a phase I clinical trial in patients with leukaemia or myelodysplastic syndromes [288] [305] [306] [307] [308] [309] [310] [311] . However, it must also be noted that in a study on the effects of HDAC inhibitors in adipocytes which included TSA and VPA it was found that VPA reduced leptin mRNA levels while TSA did not, suggesting that VPA therapy may be associated with altered leptin homeostasis contributing to weight gain in vivo, and therefore other HDAC inhibitors may not cause similar effects in relation to obesity and insulin resistance [312] .
HDAC inhibitors have also been shown to up-regulate NF-B driven pro-inflammatory cascades [313, 314] , albeit within a neural setting. Nevertheless this may also be true for multiple tissue types. In addition, HDi have also been shown to activate NF-B, and to sustain the activation of NF-B by delaying IB␣ mRNA resynthesis [315, 316] .
Within the clinical setting, other studies have shown the ineffectiveness of phenylbutyrate on relieving ER Stress in patients with ␣-1-antitrypsin deficiency [317] . [328] , rescue of protein trafficking in the lysosomal storage disorder Fabry disease [329] , correction of autodominant hypoparathyroidism induced apoptosis [330] and relief of ER stress mediated programmed cell death in arabadopsis [331] .
Do HDAC inhibitors target genes or help chaperone activity as their primary response?
Other 334, 335] , malonate toxicity [336] , rotenone [337, 338] , thapsigargin [339] 236, 261, [340] [341] [342] [343] [344] [345] , through the induction of Hsp90 [345] . Other lung conditions for which beneficial responses have been observed using HDi as chemical chaperones include respiratory distress syndrome [346] , and emphysema [54] .
Benefits accruing to the use of HDi as chemical chaperones in the liver have also been described. In one instance PB was used to protect liver cells from ER stress mediated apoptosis induced by liver ischaemia [56] , enhances the cell surface expression and transport capacity of mutated bile salt export pumps [347] [195] . VPA was also shown to protect cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3 [348] . 
